

Unpacking the Pipeline: Clearway Health’s Expert Insights on Specialty Medications

Our 10 Most Anticipated Specialty Pharmacy Medications in 2025

Clearway Health’s specialty pharmacy services create sustainable assets and build lasting legacies for hospitals and health systems, providing a service that every patient deserves. Our team began at Boston Medical Center Health System, improving access to care and managing the complex medication needs of vulnerable patient populations.

Our exclusive focus is transforming specialty pharmacy, and we have proven expertise and results in expanding our partner clients’ access to vital new medications approved by the FDA. This has a waterfall effect of expanding patient access to the latest and most innovative medications, improving their health outcomes and the overall vitality of the organizations and communities we serve.

Our specialty pharmacy team are experts in new medications that are recently approved or available in the market, as well as what’s up and coming. In areas like oncology, biosimilars, rare disease orphan

drugs and new medications for COPD, hemophilia, cystic fibrosis and heart disease, there’s been significant progress in medication therapies. We help our partner clients understand the landscape and navigate how to add these medications to their formularies so their patients can see the benefits faster.

2024 delivered notable advancements in the FDA approval of treatments for rare diseases, with 43% of all novel drug approvals classified as first-in-class and 54% designated as orphan drugs. These approvals offer new hope to patients with conditions that previously had limited therapeutic options.

Here are 10 growth driver specialty medications we are closely tracking and educating our hospital and health system partners about. Together, we pioneer providing innovative therapies to deliver optimal clinical outcomes to every patient, every time.

Alhemo

Manufactured by **Novo Nordisk**
Approved on 12.20.2024

Indication	Hemophilia
Attribute	Rare Disease/Orphan Drug; Drugs with biomarker

Alyftrek

Manufactured by **Vertex**
Approved on 12.20.2024

Indication	Cystic Fibrosis
Attribute	Rare Disease/Orphan Drug; Drugs with biomarker

Attruby

Manufactured by **BridgeBio**
Approved on 11.22.2024

Indication	Transthyretin amyloid cardiomyopathy (ATTR-CM)
Attribute	Rare Disease/Orphan Drug; Drugs with biomarker

Duvyzat

Manufactured by **Italfarmaco**
Approved on 3.21.2024

Indication	Duchenne muscular dystrophy
Attribute	Rare Disease/Orphan Drug;

Ensacove

Manufactured by **Xcovery Betta**
Approved on 12.18.2024

Indication	Non-small cell lung cancer
Attribute	Drugs with biomarker

Itovebi

Manufactured by **Roche Genentech**
Approved on 10.10.2024

Indication	Breast Cancer
Attribute	Drugs with biomarker

Lazcluze

Manufactured by **YuHan Genosoco Johnson & Johnson**
Approved on 8.19.2024

Indication	Non-small cell lung cancer
Attribute	Drugs with biomarker

Revuforj

Manufactured by **Syndax**
Approved on 11.15.2024

Indication	Leukemia
Attribute	Rare Disease/Orphan Drug; First in class approval; Drugs with biomarker

Rezdiffra

Manufactured by **Madrigal**
Approved on 3.14.2024

Indication	Metabolic Dysfunction-Associated Steatohepatitis
Attribute	First in class approval

Voranigo

Manufactured by **Agios Servierw**
Approved on 8.06.2024

Indication	CNS Cancer
Attribute	Rare Disease/Orphan Drug; Drugs with biomarker

Ready to transform your specialty pharmacy program?

A specialty pharmacy program is a transformative asset for any hospital or health system. For more information on specialty pharmacy programs, including the impact of new and upcoming medications and unlocking payer and PBM networks, visit www.clearwayhealth.com/connect

